Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Suresh Senan Clear advanced filters

  • Analysis of the radiotherapy facilities in 33 European countries has shown considerable disparity across the continent, with countries in eastern and southeastern Europe being largely underequipped compared with northern and western countries. Timely investment in the radiotherapy infrastructure is required to address the growing burden of cancer care.

    • Suresh Senan
    • Ben J. Slotman
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 10, P: 188-190

  • Advances in cancer immunotherapy have led to clinical trials of immunotherapy-based neoadjuvant treatments for early stage non-small-cell lung cancer. Evidence for priming of the immune system using both preoperative short-course radiotherapy and immunotherapy in this setting has now emerged from a randomized phase II study incorporating pathological and immunological end points.

    • Famke L. Schneiders
    • Suresh Senan
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 18, P: 545-546

  • Patients with oligometastases who develop a small number of metastatic lesions might achieve long-term survival with the use of ablative surgery or stereotactic radiotherapy. More patients are receiving aggressive treatment for oligometastatic disease, yet long-term survival might not be due to the treatments themselves, but rather to the selection of patients with slow-growing indolent disease. The authors examine the key evidence supporting or refuting the existence of an oligometastatic state and its appropriate treatment.

    • David A. Palma
    • Joseph K. Salama
    • Ralph Weichselbaum
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 549-557

  • Renal cell carcinoma (RCC) is largely percieved to be radioresistant, owing to the failure of several clinical trials involving fractionated radiotherapy. However, following the availability of new technologies, which enable the delivery of ablative doses of radiation, in fewer fractions, excellent responses have been observed among patients with RCC. In this Review, the authors describe the evidence supporting the use of ablative-dose radiotherapy, either alone, or in combination with other therapies in patients with RCC.

    • Shankar Siva
    • Gargi Kothari
    • Simon S. Lo
    Reviews
    Nature Reviews Urology
    Volume: 14, P: 549-563